Clasp is pioneering precision in immuno-oncology through next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations common across hard-to-treat cancers. With their unique properties, our TCEs are adaptable for application across a variety of cancers with high unmet need. Focus/Therapeutic Area: Oncology Stage/Status: Series A Website: https://www.clasptx.com/
Clasp Therapeutics Read More »
Crosslink is engineering cancer medicines that conditionally assemble in the tumor microenvironment. Our technology can be adapted to multiple therapeutic modalities, improving safety and efficacy. Focus/Therapeutic Area: Oncology Stage/Status: Seed Website: —
Crosslink Therapeutics Read More »
With a novel approach to precision oncology, Tasca Therapeutics is unlocking post-translational modification of proteins by utilizing our state-of-the-art chemical biology and computational approaches, and combining with inhibition at key metabolic nodes to generate drugs for previously considered undruggable targets. Tasca is focused on using its proprietary platform to develop small molecule drugs for hard-to-treat
Tasca Therapeutics Read More »
Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection. By leveraging the natural power of the immune response system, we are able to utilize fusion protein technology to attack difficult tumor targets throughout the body. Focus/Therapeutic Area: Oncology Stage/Status: Seed Website: https://www.xenimmune.com
